Compare CGNX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | KYMR |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 1989 | 2020 |
| Metric | CGNX | KYMR |
|---|---|---|
| Price | $58.38 | $84.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 24 |
| Target Price | $46.45 | ★ $105.96 |
| AVG Volume (30 Days) | ★ 1.9M | 738.5K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ 9.80 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $994,359,000.00 | $43,735,000.00 |
| Revenue This Year | $9.46 | $18.36 |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $63.28 | ★ N/A |
| Revenue Growth | ★ 8.73 | N/A |
| 52 Week Low | $22.67 | $19.45 |
| 52 Week High | $49.76 | $103.00 |
| Indicator | CGNX | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 84.83 | 65.66 |
| Support Level | $42.08 | $76.52 |
| Resistance Level | $44.27 | $78.91 |
| Average True Range (ATR) | 1.81 | 3.50 |
| MACD | 1.31 | 1.18 |
| Stochastic Oscillator | 94.23 | 99.43 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.